Hereditary Angioedema: On-demand Treatment and Long-term Prophylaxis - A Global Reality.
Modern hereditary angioedema drugs work well, yet billions face barriers to access—this review advocates for equitable global treatment standards.
This review from Royal Free London summarizes clinical trial evidence behind licensed HAE medications and highlights under-representation of global access perspectives in the HAE literature, with many patients in low- and middle-income countries unable to access modern contact-system-targeting therapies. The review synthesizes on-demand options (C1-INH concentrate, icatibant, lanadelumab) and long-term prophylaxis evidence, providing a reference for global care standard advocacy.
What the study was
- Study design
- Narrative review
- Population
- Patients with HAE due to C1-INH deficiency/dysfunction globally, including resource-limited settings
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Clinical and Experimental Immunology
Why it surfaced
Rare disease review addressing global access gap for HAE treatments; unmet need emphasis relevant to T9 watchlist; Clin Exp Immunol publication with clinical trial evidence synthesis.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.